MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced today results of its initial
Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential
treatment of children with asthma. The Company announced that the clinical
AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
LONDON, Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did
not meet its co-primary endpoints: asthma control as assessed by changes from baseline i...
Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
- Study showed no consistent differences in bone mineral density at the
lumbar spine and total hip between Advair Diskus 250/50 (fluticasone
propionate and salmeterol inhalation powder) and salmeterol
- Study provides support for long term use of Advair(R) in patients
Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
-Webcast to Be Held at 4:30 p.m. ET today-
SAN CARLOS, Calif., March 17 /PRNewswire-FirstCall/ -- Nuvelo, Inc.
(Nasdaq: NUVO ) today announced that data from the Phase 2 program in
catheter occlusion (CO), known as SONOMA-3 (Speedy Opening of
Non-functional and Occluded cathete...
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
- Response at 12 weeks is a powerful predictor of eventual treatment success -
BOSTON, Nov. 2 /PRNewswire/ -- Roche today announced final results from
the REPEAT study, which demonstrated that treatment with once-weekly
PEGASYS(R) (peginterferon alfa-2a) and dai...
Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet
LONDON, March 19, 2007-AstraZeneca today announced that its
collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) revealed
first results from the ARISE (Aggressive Reduction of Inflammation
Stops Events) phase III clinical outcomes trial which studied
AGI-1067, an investigational anti-atheroscle...
Large Study Shows that Presence of Neutralizing Antibodies Did Not
Predict Clinical Response to Betaseron Treatment
WAYNE, N.J., April 02, 2007 /PRNewswire/ -- Berlex, Inc., a U.S.
affiliate of Bayer Schering Pharma AG, Germany, announced today the
results of a retrospective study demonstrating that the presence of
neutralizing antibodies (NAbs) that can develop in response to
Betaseron(R) (interferon beta-1b) ...
Regular Yoga Practice Is Associated With Mindful Eating
...e who practice yoga gained less weight over a 10-year period than those who did
not. This was independent of physical activity and dietary patterns. We hyp...ex was lower among participants who practiced yoga as compared to those who did
not (an average of 23.1 vs. 25.8, respectively).
Higher scores on th...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...9 increased by $1.7 million and $3.3 million compared to an increase of $1.5 million and $3.0 million for the same periods in 2008. This new standard did
not impact Isis' cash, cash equivalents and short-term investments but decreased the carrying value of Isis' $162.5 million convertible notes to $121....
Study Shows Brain Fitness can Save Medicare Billions
...dy recently published in BMC Health Services Research, a leading peer-reviewed health services journal.
Researchers found that participants who did
just ten hours of special computerized brain exercises had better health outcomes, lowering projected Medicare costs by hundreds of dollars per year. ...
Scientists Discover Origin of Malaria
... way that modern pandemics do, namely by jumping from animals to humans" Wolfe said. "We now know that malaria, while at least thousands of years old, did
not originate in humans but rather was introduced into our species, presumably by the bite of a mosquito that had previously fed on a chimpanzee."
Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin
... skin does not have the same elasticity as it once did
and that it is drier than normal.
In order ... the study concluded that estrogen supplementation did
not provide any significant improvement in sun-dam...men who began HRT at the onset of menopause -- and did
not wait to start treatment like the other group -...
Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease
... from respondents who met the screening criteria. The survey included 889 U.S. women with postmenopausal osteoporosis and 912 postmenopausal women who did
not have osteoporosis; all women were aged 50+. The data were weighted to reflect age, race/ethnicity, education, region and household income. Propens...
FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
This decision comes following labeling discussions with the FDA that did
result in agreement in time to meet the PDUFA date.
The FDA did
not identify safety concerns regarding INTUNIV in the
Complete Response let...
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
...TON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did
not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
...he group treated with R788 (fostamatinib disodium) did
not report significantly higher ACR 20, ACR 50, AC...tive components (CRP and ESR)* of these ACR scores did
show a statistically significant difference; howev..., the subjective reported response rate components did
not as compared to placebo. Although the ACR score...
International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
The patient has experienced increasing pain on her right side for the past 31 years, a persistent cough and wheezing. As the pain increased so did
her medication. Using the new imaging approach, Dr. Harbut was able to show the progression of the patient's pleural plaque over a three year period, ...
Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class
...yl-tRNA synthetase. While tRNA synthetases play an essential role in protein synthesis in all forms of life, these dominant mutations in CMT patients did
not seem to manifest the disease through disruption of those protein synthesis activities. When the mutations found in humans are introduced into the...
PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it
...een Alzheimer's and obesity or high blood pressure. Sixty-six percent (66%) did
not know that high stress is a risk factor for dementia, and 34% did
not know that physical exercise is a protective factor.
On the po...
Results From Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline
...so appeared to increase brain DHA levels, based on a measured increase of DHA in study participants' cerebrospinal fluid (CSF). However, DHA treatment did
not slow the rate of change on tests of mental function (ADAS-cog), global dementia severity status (CDR-SOB), activities of daily living (ADL), or be...
Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows
...ar a custom ACL brace. All patients who underwent the surgery utilized a soft tissue graft with anatomically placed tunnels and fixation devices that did
not cross the growth plate. Patients were also followed for a minimum of one-year post-operatively with no growth disturbances being noted.
Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story
...ven with good treatment by the same doctors, African-American patients with one of these three cancers faced a significantly higher risk of death than did
other patients, ranging from a 21% higher risk for those with prostate cancer to a 61% higher risk for ovarian cancer patients.
The elimination o...
Number of Patients With Dementia on the Rise
...cause with my family history," Sabin says. "I felt studies I was participating in would help other people so that they won't have to go through what I did
with my own relatives."
For more information, please visit:
Michigan Alzheimer's Disease Research Center (MADRC)
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
...provement in EASI score over the
whole treatment period for ProtoCure emulsion cream as a sign of positive
treatment effect. The EASI score difference did
not reach statistical
significance when compared to placebo, mainly due to the small number of
"We are very pleased with the ...
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
...e titled, "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did
not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that Guidance. Th...
Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation
...71 patients, in fact, had significantly better complete remission than the 56 patients who had been irradiated.
"The bottom line is that not only did
we get outstanding treatment responses in these patients, many of whom would have otherwise received irradiation, but they will have a better quality ...
ADHD Genes Found; Known to Play Roles in Neurodevelopment
...er work must be done before genetic findings lead to ADHD treatments.
The National Institutes of Health provided grant support for the study, as did
the University of Pennsylvania , the Pennsylvania Department of Health, the Cotswold Foundation and the ADHD: Climbing to a Cure Foundation. Elia, Wh...
Alfacell Provides Shareholder Update
...valuable compounds realize their full potential.
As you are aware, we did
not meet our primary endpoint of overall survival in our Phase IIIb clinica...al in patients suffering from unresectable malignant mesothelioma (UMM). We did
however; achieve statistical significance with a subgroup of patients who f...
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
...benefit in overall survival, compared to those who received induction chemotherapy alone.
"We are disappointed that this study with lestaurtinib did
not demonstrate a benefit for this patient population but we remain committed to oncology clinical research and developing innovative therapies for li...
Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
...million for SMA research. Families of SMA funds and directs the leading SMA research programs. Families of SMA has created hope for our community that did
not exist in 1984. Our support comes from generous individual donations and numerous fundraising events held by volunteer families and our chapters.
Scottsdale Facility to Be First in U.S. to Showcase True REST Technology
... outpatient treatment programs. At the end of four years of follow-up, 43 percent remained continuously sober and drug-free. None of the control group did
so for eight months of follow-up.
Treatment in the form of floating in huge tanks of saltwater, so-called "floating," is effective for chronic st...
New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
...-identified as the high spinal block group--PVI decreased. In patients who did
not reach the C-area--identified as the non-high spinal block group--PVI of the upper limbs did
not change significantly. Researchers summarized that high spinal block di...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
...t BSA involved with skin symptoms of PsA, 200 were evaluated at two years. PASI 75 was also observed in 33 of 48 patients receiving SIMPONI 50 mg who did
not change dose and 73 of 96 patients receiving SIMPONI 100 mg. Thirty-five of 56 patients receiving SIMPONI 50 mg who switched to SIMPONI 100 mg in e...
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
...w/stem cell transplantation centers in the US and France. Although orBec(R) did
not achieve statistical significance in the primary endpoint of its pivotal... median time-to-treatment failure through Day 50 (p-value 0.1177), orBec(R) did
achieve statistical significance in other key secondary endpoints such as t...
New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients
...EART CONDITIONS UNTREATED
More than 75 percent of patients studied did
not have aortic valve replacement surgery even though they met established ...severe aortic stenosis (AS) were referred for surgery. The other 75 percent did
not have valve replacement (AVR) surgery even though they met echocardiogra...
SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
...nt to understand: it is these sicker patients, who did
not meet the inclusion criteria for the trial base...nfortunately, the majority of the BARI-2D patients did
not receive drug-eluting stents, which have been s...tiated and many of the early patients in the trial did
not receive the care we now know to be most effect...
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
... fasting plasma glucose (FPG) and preprandial blood glucose < 110 mg/dl, and bedtime blood glucose < 130 mg/dl. FPG, Lantus(R) dose, and weight did
not differ significantly among the 3 arms. Overall incidence and severity of adverse events (AEs) were comparable among the 3 treatment arms. The most...
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
...ultiple secondary endpoints associated with cardiovascular risk. Lorcaserin did
not result in increased risk of depression and was not associated with the ...s (BMI 27 to less than 30) with at least one co-morbid condition. The trial did
not include any dose titration or run-in period. Patients were randomized i...
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
...at blood cells from immunized mice produced gamma interferon in response to the vaccine, while the blood cells from mice in the various control groups did
not. Gamma interferon, a cytokine that helps regulate the body's immune response, is considered to be a good indicator of protection against TB and o...
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
in patients receiving BSI-201 combined with chemotherapy. BSI-201 did
to the frequency or severity of adverse events associated with chem...e survival
together with the responses seen in this study are promising. We did
observe added toxicities. BSI-201 may provide a potential new treatment...